1. Clinical validation of a non-invasive electrodermal biofeedback device useful for reducing chronic perceived pain and systemic inflammation
- Author
-
George P. Chrousos and Dario Boschiero
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Pain ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Stress ,Systemic inflammation ,Placebo ,Biofeedback ,C-reactive protein ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,medicine ,Humans ,Pain Management ,Electrodermal biofeedback ,Aged ,Morning ,Aged, 80 and over ,Inflammation ,Greece ,biology ,business.industry ,Chronic pain ,Biofeedback, Psychology ,Pain Perception ,Chronic inflammation ,Galvanic Skin Response ,General Medicine ,Middle Aged ,medicine.disease ,Treatment Outcome ,Mood ,Equipment and Supplies ,biology.protein ,Physical therapy ,Original Article ,Female ,Chronic Pain ,medicine.symptom ,RegMatEx ,business - Abstract
Background This study was performed to evaluate the potential clinical usefulness of a new non-invasive electrodermal biofeedback device in reducing perceived pain levels and chronic systemic inflammation. Materials and methods This multicenter study was designed and coordinated by BioTekna, included 20 general practice medical centers, took place between June 2010 and January 2011, and was validated clinically at the National and Kapodistrian University of Athens, Greece. The study participants were 1015 Caucasian men (401) and women (614), while the placebo-treated controls were 950 Caucasian men (500) and women (450). Patients were aged between 30 and 86 years (average age about 50 years) and all suffered from chronic pain and other medically unexplained symptoms (MUS). The RegMatEx electrodermal biofeedback device (brand BioTekna - Biomedical Technologies, Marcon, Venice, Italy) was used to evaluate the clinical efficacy of electrodermal biofeedback in reducing the level of pain perceived by decreasing the chronic systemic inflammation of the subjects. All subjects received 6 × 30 min sessions of electrodermal or placebo biofeedback given twice a week over 3 weeks. Perceived pain was evaluated using the Numeric Rating Scale (NRS) for pain, while systemic inflammation was examined with measurements of morning circulating C-reactive protein (CRP) concentrations. Results Perceived pain in the treatment group was significantly lessened in the NRS scale (p
- Published
- 2019
- Full Text
- View/download PDF